Qsemble Capital Management LP Buys Shares of 10,743 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Qsemble Capital Management LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, HoldingsChannel.com reports. The fund purchased 10,743 shares of the company’s stock, valued at approximately $1,238,000.

Other large investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the second quarter valued at approximately $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth $32,000. EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at about $35,000. Finally, Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.6 %

Shares of NASDAQ NBIX opened at $127.91 on Wednesday. The firm has a market capitalization of $12.95 billion, a P/E ratio of 34.29 and a beta of 0.35. The firm’s 50-day moving average price is $118.83 and its 200-day moving average price is $131.74. Neurocrine Biosciences, Inc. has a 1-year low of $110.52 and a 1-year high of $157.98.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Robert W. Baird upped their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Raymond James restated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, Royal Bank of Canada lowered their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.